c 283

Nitracrine dihydrochloride is an acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.

OPC-28326 是一种特异性的 α2-肾上腺素能受体拮抗剂，可作为外周血管扩张剂。 OPC-28326 抑制 α2A-、α2B- 和 α2C- 肾上腺素能受体，Ki 分别为 2040、285 和 55nM。

Phlorizin (Phloridzin) 是非选择性的SGLT 抑制剂，也是Na+/K+-ATPase 抑制剂，对于hSGLT1和hSGLT2的Ki 值分别为 300 和 39 nM。

N-Trifluoroacetyladriamycin is a metabolite of Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar). Valrubicin is a chemotherapy drug utilized to treat bladder cancer. Valrubicin is the anthracycline doxorubicin analog and is administ

Valopicitabine, a NS5B inhibitor, is used potentially for the treatment of HCV infection.

Lifirafenib (Beigene-283) 是新型高效的Raf 激酶和EGFR 抑制剂，对重组BRafV600E 和EGFR 的IC50值分别为 23 和 29 nM。

Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1[1][2][3][4]. [1]. J Musial, et al. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation. 1990 Jul;82(1):261-73.[2]. M Sato, et al. Echistatin is a potent inhibitor of bone resorption in culture. J Cell Biol. 1990 Oct;111(4):1713-23.[3]. C C Kumar, et al. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J Pharmacol Exp Ther. 1997 Nov;283(2):843-53.[4]. I Wierzbicka-Patynowski, et al. Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins. J Biol Chem. 1999 Dec 31;274(53):37809-14.